Lorena Filomeno
Via Elio Chianesi 53
Rome, 00144, Italy
Rome, 00144, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2026
Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.
Journal: NPJ breast cancer
Published: January 23, 2026
Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 23, 2025
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer.
Journal: Molecular oncology
Published: September 24, 2025
Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.
Journal: The oncologist
Published: June 13, 2025
Adherence to Aromatase Inhibitor Therapy in Breast Cancer: Insights From a Multicenter Italian Study.
Journal: The breast journal
Published: November 25, 2024
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors.
Journal: Breast (Edinburgh, Scotland)
Published: October 22, 2024
DNA Damage Response in Early Breast Cancer: A Phase III Cohort in the Phobos Study.
Journal: Cancers
Published: June 26, 2024
Breast and cervical cancer in transgender men: literature review and a case report.
Journal: Therapeutic advances in medical oncology
Published: January 30, 2024
HER2 mutation as an emerging target in advanced breast cancer.
Journal: Cancer science
Published: January 15, 2024
Last Updated: 09/26/2026